Hospira received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.
Inflectra (infliximab) is a biosimilar medicine to the reference medicinal product, Remicade (infliximab), and is the first monoclonal antibody therapy to reach a positive opinion following review via the EMA biosimilars regulatory pathway. A biosimilar developed in-line with EU requirements can be considered a therapeutic alternative to an existing biologic, with comparable quality, efficacy and safety to the reference product.
Biologic medicines have led to vast improvements in the treatment of conditions such as rheumatoid arthritis and inflammatory bowel disease, but they also represent one of the biggest medical expenditures in many countries.
Inflectra specifically targets tumor necrosis factor (TNF) alpha, a protein in the body that contributes to the painful inflammation seen in rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. The drug's safety, efficacy and tolerability have been established through a comprehensive clinical trial program. In a phase III randomized, double-blind study, Inflectra met its primary endpoint of therapeutic equivalence to the reference product. In the study, 73.4% of patients receiving Inflectra achieved a greater than 20% improvement in RA symptoms after 30 weeks of treatment (using the ACR20 scoring system), compared with 69.7% treated with reference infliximab. The safety and tolerability of Inflectra was also demonstrated to be comparable to Remicade, supporting its approval.
In 2009, Hospira entered into an agreement with South Korean-based biopharmaceutical company, Celltrion, which is developing eight monoclonal antibody biosimilars. Under the terms of the agreement, Hospira obtained the rights to Inflectra in Europe, the United States, Canada, Australia and New Zealand.
The European Commission reviews the recommendations of the CHMP. The final decision on approval, usually granted within three months of CHMP opinion, will be applicable to all European Union (EU) and European Economic Area (EEA) countries.
Hospira is the only U.S.-based company with biosimilars on the European market, including Retacrit which was launched in Europe in early 2008 and Nivestim, which entered the European market in 2010 and Australian market in 2011.
"In a time when there is mounting pressure on healthcare budgets worldwide, Inflectra provides an opportunity to increase patient access to more affordable biologic therapy while maintaining high quality standards," said Richard Davies, Senior Vice President and Chief Commercial Officer, Hospira.
 Weise M. et al. Blood. 2012; 120: 5111-5117
 Bendtzen, K. Immunotherapy. 2012; 4(11): 1167-1179.
 Hospira Inc, 2013, Data on file.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Exodus 2100: Due To Climate Change
- What Lies Beneath West Antarctica?
- Evidence Points To Widespread Loss Of Ocean Oxygen By 2030s
- Scientists Discover Oral Sex In Spiders
- Professor Frenkel: Why Shouldn't We Drop Algebra From Our Education System?
- The Geology Of Wine
- How To Make Women's Tennis More Competitive
- "This is total nonsense. The climate models are highly accurate and getting more accurate every..."
- "So in short, all carbon based life forms are the enemy... The solution? Charging carbon credits..."
- "I remember when I was young network specials airing on the subject of climate change (often then..."
- "God punishes heathens in many ways. This is just one of them. Repent...."
- "Africa is doomed because of overpopulation. You have millions of people destroying the land and..."
- 3 Reasons Aerial Pesticides Are Not Causing Autism
- Most Stores Refuse E-Cigarette Sales to Minors
- Vitamin C Conundrum for the Organic Crowd
- Newsweek Journalist Loses His Mind, Time-Traveling Radioactivity And More Media Links
- This Single-Celled Organism Is Capable Of Learning
- Study Says Bilingual Kids’ Brains Are Smarter & Faster
- UC San Diego bioengineers create first online search engine for functional genomics data
- UK Health Check has only modest impact on risk factors for cardiovascular disease
- Adult brain prunes branched connections of new neurons
- Five new breast cancer genes and range of mutations pave way for personalized treatment
- Quantum sensors for high-precision magnetometry of superconductors